BLIS Technologies (BLT) H2 2025 earnings summary

Executive summary

• Achieved revenue of $12.6m for FY25, up 10% year-over-year, with EBITDA of $1.0m (+26%) and NPAT of $0.8m (+30%).

• Growth driven by finished product sales, B2C channel expansion, and strong North America and Asia Pacific performance.

• Cash position strengthened to $9.7m, with operating cash surplus of $1.8m (+70%).

• Navigated unexpected intellectual property issues and supply chain changes, while advancing China regulatory approvals.

• Marked 25th anniversary, with continued focus on innovation, ESG, and B Corp certification journey.

Financial highlights

• Revenue: $12.6m (+10% YoY); EBITDA: $1.0m (+26% YoY); NPAT: $0.8m (+30% YoY); EPS: 0.07c.

• Cash generated from operations: $1.8m (+70% YoY); cash and short-term deposits: $9.7m.

• B2B revenue: $8.1m (+1% YoY, 64% of total); B2C revenue: $4.5m (+29% YoY, 36% of total).

• Amazon US sales: $2.0m (+30% YoY); BLIS web store: $0.6m (+19% YoY).

• Shareholder equity: $12.3m; NTA per share: 0.82c; return on equity: 6.8%.

Outlook and guidance

• Entering FY26 with cautious optimism amid mixed macroeconomic conditions; demand for science-backed probiotics expected to grow.

• Focus on revenue growth in key countries, innovation in oral health, regulatory advancement, and go-to-market optimization.

• China regulatory review pending; new fermentation partner to support future supply from 2026.